Symbols / HUMA Stock $1.06 -2.31% Humacyte, Inc.

Healthcare • Biotechnology • United States • NMS
HUMA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Laura E. Niklason M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 284.47M
Enterprise Value 252.19M
Income -95.22M
Sales 2.02M
FCF (ttm) -64.81M
Book/sh 0.05
Cash/sh 0.22
Employees 184
Insider 10d —
IPO Dec 01, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.06
PEG —
P/S 141.11
P/B 20.29
P/C —
EV/EBITDA -2.40
EV/Sales 125.09
Quick Ratio 3.02
Current Ratio 3.93
Debt/Eq 572.10
LT Debt/Eq —
EPS (ttm) -0.63
EPS next Y -0.26
EPS Growth —
Revenue Growth -4.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-10
Earnings (prior) 2026-05-13
ROA -51.48%
ROE -4.09%
ROIC —
Gross Margin 0.00%
Oper. Margin -57.04%
Profit Margin 0.00%
Shs Outstand 269.64M
Shs Float 190.57M
Insider Own 7.51%
Instit Own 22.17%
Short Float 18.21%
Short Ratio 5.75
Short Interest 40.14M
52W High 2.84
vs 52W High -62.85%
52W Low 0.55
vs 52W Low 92.87%
Beta 2.46
Impl. Vol. 12.50%
Rel Volume 1.13
Avg Volume 8.05M
Volume 9.09M
Target (mean) $2.10
Tgt Median $2.00
Tgt Low $1.00
Tgt High $4.00
# Analysts 5
Recom Buy
Prev Close $1.08
Price $1.05
Change -2.31%
About

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.10
Mean price target
2. Current target
$1.06
Latest analyst target
3. DCF / Fair value
$-4.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.06
Low
$1.00
High
$4.00
Mean
$2.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-11 main HC Wainwright & Co. Buy → Buy $4
2026-06-08 reit BTIG Buy → Buy $2
2026-06-01 main Benchmark Speculative Buy → Speculative Buy $2
2026-05-26 reit HC Wainwright & Co. Buy → Buy $3
2026-05-14 main TD Cowen Buy → Buy $2
2026-05-13 main BTIG Buy → Buy $2
2026-04-28 main D. Boral Capital Buy → Buy $25
2026-04-28 reit BTIG Buy → Buy $3
2026-04-24 main D. Boral Capital Buy → Buy $25
2026-04-21 main D. Boral Capital Buy → Buy $25
2026-04-08 main Barclays Overweight → Overweight $2
2026-03-31 down Benchmark Buy → Speculative Buy $1
2026-03-30 main Piper Sandler Neutral → Neutral $1
2026-03-30 main TD Cowen Buy → Buy $1
2026-03-27 main D. Boral Capital Buy → Buy $25
2026-03-27 main BTIG Buy → Buy $3
2026-03-19 main D. Boral Capital Buy → Buy $25
2026-03-17 main D. Boral Capital Buy → Buy $25
2026-02-19 main D. Boral Capital Buy → Buy $25
2026-02-10 reit BTIG Buy → Buy $6
News
RSS: Latest HUMA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-19 SEBELIUS KATHLEEN G Director — 56,818 $0.88 $50,000
2026-05-18 CONSTANTINO MICHAEL T Director — 11,000 $0.89 $9,840
2026-05-18 SANDER DALE A Chief Financial Officer — 45,887 $0.90 $41,147
2026-05-18 PARIKH SHAMIK J Officer — 45,887 $0.90 $41,147
2025-11-14 SANDER DALE A Chief Financial Officer — 311,100 $0.00 $0
2025-11-14 PARIKH SHAMIK J Officer — 311,100 $0.00 $0
2025-08-20 DOUGAN BRADY W Director — 2,241,045 $1.58 $3,733,191
2025-08-20 NIKLASON LAURA E Chief Executive Officer — 2,241,045 $1.58 $3,733,191
2025-04-14 SCHEESSELE WILLIAM JOHN Officer — 6,493 $1.54 $9,999
2025-04-10 SANDER DALE A Chief Financial Officer — 20,000 $1.53 $30,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.04
0.00
0.00
0.00
Operating Revenue
2.04
0.00
0.00
0.00
Cost Of Revenue
9.70
0.00
—
—
Reconciled Cost Of Revenue
9.70
0.00
—
—
Gross Profit
-7.66
0.00
—
—
Operating Expense
100.47
-12.17%
114.40
+14.34%
100.05
+18.29%
84.58
Research And Development
69.30
-21.78%
88.60
+15.74%
76.55
+21.01%
63.26
Selling General And Administration
31.17
+20.82%
25.80
+9.80%
23.50
+2.68%
22.88
General And Administrative Expense
31.17
+20.82%
25.80
+9.80%
23.50
+2.68%
22.88
Salaries And Wages
—
—
-3.11
0.00
Other Gand A
31.17
+20.82%
25.80
+9.80%
23.50
+2.68%
22.88
Other Operating Expenses
—
—
—
-1.56
Total Expenses
110.17
-3.69%
114.40
+14.34%
100.05
+18.29%
84.58
Operating Income
-108.14
+5.47%
-114.40
-14.34%
-100.05
-18.29%
-84.58
Total Operating Income As Reported
-108.14
+5.47%
-114.40
-14.34%
-100.05
-18.29%
-84.58
EBITDA
-22.24
+83.18%
-132.23
-37.09%
-96.46
-4045.11%
2.44
Normalized EBITDA
-98.20
+4.75%
-103.10
-18.70%
-86.86
-17.80%
-73.74
Reconciled Depreciation
7.34
+2.16%
7.19
-6.85%
7.72
-5.98%
8.21
EBIT
-29.58
+78.78%
-139.42
-33.83%
-104.18
-1707.06%
-5.76
Total Unusual Items
75.97
+360.79%
-29.13
-203.53%
-9.60
-112.60%
76.18
Total Unusual Items Excluding Goodwill
75.97
+360.79%
-29.13
-203.53%
-9.60
-112.60%
76.18
Special Income Charges
37.20
+212.58%
-33.05
-253.91%
-9.34
-112.32%
75.77
Other Special Charges
22.27
—
-0.69
—
Restructuring And Mergern Acquisition
-59.47
-279.96%
33.05
+229.69%
10.02
+113.23%
-75.77
Net Income
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Pretax Income
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Net Non Operating Interest Income Expense
-8.66
-67.47%
-5.17
-356.98%
-1.13
+68.30%
-3.57
Interest Expense Non Operating
11.25
+21.27%
9.28
+40.58%
6.60
+6.44%
6.20
Net Interest Income
-8.66
-67.47%
-5.17
-356.98%
-1.13
+68.30%
-3.57
Interest Expense
11.25
+21.27%
9.28
+40.58%
6.60
+6.44%
6.20
Interest Income Non Operating
2.59
-36.96%
4.10
-24.93%
5.47
+107.95%
2.63
Interest Income
2.59
-36.96%
4.10
-24.93%
5.47
+107.95%
2.63
Other Income Expense
75.97
+360.79%
-29.13
-203.53%
-9.60
-112.60%
76.18
Gain On Sale Of Security
38.77
+890.17%
3.92
+1605.77%
-0.26
-162.35%
0.42
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Net Income From Continuing Operation Net Minority Interest
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Net Income From Continuing And Discontinued Operation
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Net Income Continuous Operations
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Normalized Income
-116.80
+2.32%
-119.57
-18.18%
-101.18
-14.78%
-88.15
Net Income Common Stockholders
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Diluted EPS
-0.26
+79.37%
-1.26
-17.76%
-1.07
-791.67%
-0.12
Basic EPS
-0.26
+79.37%
-1.26
-17.76%
-1.07
-791.67%
-0.12
Basic Average Shares
158.16
+33.49%
118.48
+14.56%
103.42
+0.36%
103.05
Diluted Average Shares
158.16
+33.49%
118.48
+14.56%
103.42
+0.36%
103.05
Diluted NI Availto Com Stockholders
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
116.37
-15.60%
137.87
+7.53%
128.22
-37.24%
204.30
Current Assets
67.80
+41.66%
47.86
-42.53%
83.28
-46.00%
154.21
Cash Cash Equivalents And Short Term Investments
50.50
+12.37%
44.94
-44.14%
80.45
-47.03%
151.88
Cash And Cash Equivalents
50.50
+12.37%
44.94
-44.14%
80.45
-46.29%
149.77
Other Short Term Investments
—
—
0.00
-100.00%
2.11
Receivables
0.44
0.00
0.00
-100.00%
0.03
Accounts Receivable
0.44
0.00
0.00
-100.00%
0.03
Inventory
13.59
0.00
—
—
Raw Materials
5.82
0.00
—
—
Work In Process
6.54
0.00
—
—
Finished Goods
10.12
0.00
—
—
Prepaid Assets
—
—
—
—
Other Current Assets
3.27
+11.84%
2.92
+3.25%
2.83
+23.15%
2.30
Total Non Current Assets
48.57
-46.04%
90.01
+100.27%
44.95
-10.28%
50.09
Net PPE
47.69
+23.70%
38.55
-12.59%
44.10
-11.96%
50.09
Gross PPE
89.02
+19.27%
74.64
-1.05%
75.43
-1.11%
76.28
Accumulated Depreciation
-41.33
-14.53%
-36.09
-15.20%
-31.33
-19.65%
-26.18
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.19
+0.18%
2.19
+16.92%
1.87
+37.32%
1.36
Construction In Progress
—
—
0.00
-100.00%
0.68
Other Properties
58.86
+32.13%
44.55
-2.55%
45.71
-4.52%
47.88
Leases
27.97
+0.24%
27.90
+0.20%
27.84
+5.65%
26.36
Other Non Current Assets
0.88
-98.29%
51.46
+6018.91%
0.84
—
Total Liabilities Net Minority Interest
113.26
-40.56%
190.54
+66.15%
114.68
+31.25%
87.37
Current Liabilities
18.37
-7.93%
19.95
+8.19%
18.44
-5.81%
19.58
Payables And Accrued Expenses
9.31
-3.73%
9.67
-8.69%
10.59
+136.64%
4.48
Payables
5.40
+20.36%
4.49
-30.82%
6.49
+306.90%
1.59
Accounts Payable
5.40
+20.36%
4.49
-30.82%
6.49
+306.90%
1.59
Current Accrued Expenses
3.91
-24.60%
5.18
+26.33%
4.10
+42.38%
2.88
Pensionand Other Post Retirement Benefit Plans Current
6.63
+6.26%
6.24
+19.17%
5.24
+23.92%
4.23
Current Debt And Capital Lease Obligation
2.43
-16.76%
2.92
+13.95%
2.56
-76.46%
10.88
Current Debt
—
—
—
8.57
Other Current Borrowings
—
—
—
8.57
Current Capital Lease Obligation
2.43
-16.76%
2.92
+13.95%
2.56
+11.01%
2.31
Current Deferred Liabilities
—
—
—
0.00
Other Current Liabilities
—
1.12
+2018.87%
0.05
—
Total Non Current Liabilities Net Minority Interest
94.89
-44.38%
170.59
+77.26%
96.23
+41.95%
67.79
Long Term Debt And Capital Lease Obligation
62.42
+358.28%
13.62
-16.41%
16.29
-58.42%
39.19
Long Term Debt
35.44
—
38.60
+89.81%
20.34
Long Term Capital Lease Obligation
26.97
+98.05%
13.62
-16.41%
16.29
-13.58%
18.85
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Taxes Liabilities
—
—
—
—
Other Non Current Liabilities
13.07
-90.34%
135.30
+75.20%
77.23
+169.98%
28.61
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
3.11
+105.90%
-52.67
-488.82%
13.55
-88.42%
116.93
Common Stock Equity
3.11
+105.90%
-52.67
-488.82%
13.55
-88.42%
116.93
Capital Stock
0.02
+53.85%
0.01
+30.00%
0.01
+0.00%
0.01
Common Stock
0.02
+53.85%
0.01
+30.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
193.00
+48.43%
130.03
+25.42%
103.67
+0.43%
103.23
Ordinary Shares Number
193.00
+48.43%
130.03
+25.42%
103.67
+0.43%
103.23
Additional Paid In Capital
729.94
+15.25%
633.33
+14.97%
550.85
+1.36%
543.46
Retained Earnings
-726.85
-5.95%
-686.01
-27.67%
-537.31
-25.97%
-426.54
Total Equity Gross Minority Interest
3.11
+105.90%
-52.67
-488.82%
13.55
-88.42%
116.93
Total Capitalization
38.55
+173.20%
-52.67
-488.82%
13.55
-90.13%
137.26
Working Capital
49.42
+77.11%
27.91
-56.96%
64.83
-51.84%
134.63
Invested Capital
38.55
+173.20%
-52.67
-488.82%
13.55
-90.71%
145.84
Total Debt
64.85
+292.13%
16.54
-12.28%
18.85
-62.34%
50.07
Capital Lease Obligations
29.40
+77.80%
16.54
-12.28%
18.85
-10.90%
21.16
Net Tangible Assets
3.11
+105.90%
-52.67
-488.82%
13.55
-88.42%
116.93
Tangible Book Value
3.11
+105.90%
-52.67
-488.82%
13.55
-88.42%
116.93
Current Deferred Taxes Liabilities
—
—
—
0.00
Derivative Product Liabilities
19.39
-10.51%
21.67
+698.42%
2.71
0.00
Inventories Adjustments Allowances
-8.90
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-105.04
-7.05%
-98.12
-33.85%
-73.31
-3.06%
-71.13
Cash Flow From Continuing Operating Activities
-105.04
-7.05%
-98.12
-33.85%
-73.31
-3.06%
-71.13
Net Income From Continuing Operations
-40.83
+72.54%
-148.70
-34.24%
-110.78
-825.83%
-11.96
Depreciation Amortization Depletion
7.34
+2.16%
7.19
-6.85%
7.72
-5.98%
8.21
Depreciation
5.33
+4.39%
5.10
-9.81%
5.66
-8.00%
6.15
Amortization Cash Flow
2.02
-3.31%
2.09
+1.26%
2.06
+0.05%
2.06
Depreciation And Amortization
7.34
+2.16%
7.19
-6.85%
7.72
-5.98%
8.21
Amortization Of Intangibles
2.02
-3.31%
2.09
+1.26%
2.06
+0.05%
2.06
Other Non Cash Items
-50.32
-223.17%
40.85
+199.19%
13.65
+118.41%
-74.18
Stock Based Compensation
9.75
+58.92%
6.14
-10.12%
6.83
+10.41%
6.18
Provisionand Write Offof Assets
8.90
0.00
—
—
Asset Impairment Charge
—
—
—
0.00
Operating Gains Losses
-16.49
-321.71%
-3.91
-244.91%
2.70
+756.69%
-0.41
Gain Loss On Investment Securities
-38.77
-890.17%
-3.92
-1605.77%
0.26
+162.35%
-0.42
Gain Loss On Sale Of PPE
0.01
+25.00%
0.00
-77.78%
0.02
+200.00%
0.01
Change In Working Capital
-23.39
-7622.51%
0.31
-95.27%
6.57
+538.58%
1.03
Change In Receivables
-0.26
0.00
-100.00%
0.03
-78.62%
0.14
Changes In Account Receivables
-0.26
0.00
-100.00%
0.03
-78.62%
0.14
Change In Inventory
-21.83
0.00
—
—
Change In Prepaid Assets
-0.53
-698.86%
0.09
+122.68%
-0.39
-128.45%
1.36
Change In Payables And Accrued Expense
-0.74
-366.67%
0.28
-96.04%
6.98
+2763.36%
-0.26
Change In Accrued Expense
-1.71
-176.36%
2.24
+3.28%
2.17
+777.33%
0.25
Change In Payable
0.97
+149.59%
-1.96
-140.78%
4.81
+1045.19%
-0.51
Change In Account Payable
0.97
+149.59%
-1.96
-140.78%
4.81
+1045.19%
-0.51
Change In Other Working Capital
—
—
—
-0.17
Change In Other Current Liabilities
-0.04
+16.98%
-0.05
-6.00%
-0.05
-11.11%
-0.04
Investing Cash Flow
-0.88
+43.77%
-1.57
-808.67%
-0.17
-103.57%
4.84
Cash Flow From Continuing Investing Activities
-0.88
+43.77%
-1.57
-808.67%
-0.17
-103.57%
4.84
Net PPE Purchase And Sale
-0.88
+43.77%
-1.57
+31.05%
-2.28
-117.56%
-1.05
Purchase Of PPE
-0.88
+43.77%
-1.57
+31.05%
-2.28
-117.56%
-1.05
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.88
+43.77%
-1.57
+31.05%
-2.28
-117.56%
-1.05
Net Investment Purchase And Sale
—
0.00
-100.00%
2.11
-64.25%
5.89
Purchase Of Investment
—
—
0.00
+100.00%
-10.11
Sale Of Investment
—
0.00
-100.00%
2.11
-86.83%
16.00
Financing Cash Flow
61.49
-46.15%
114.18
+2433.46%
4.51
+411.69%
-1.45
Cash Flow From Continuing Financing Activities
61.49
-46.15%
114.18
+2433.46%
4.51
+411.69%
-1.45
Net Issuance Payments Of Debt
37.03
+1535.79%
-2.58
+92.43%
-34.07
-1619.64%
-1.98
Issuance Of Debt
39.78
0.00
—
0.00
Repayment Of Debt
-2.75
-6.79%
-2.58
+92.43%
-34.07
-1619.64%
-1.98
Long Term Debt Issuance
39.78
0.00
—
0.00
Long Term Debt Payments
-2.75
-6.79%
-2.58
+92.43%
-34.07
-1619.64%
-1.98
Net Long Term Debt Issuance
37.03
+1535.79%
-2.58
+92.43%
-34.07
-1619.64%
-1.98
Net Common Stock Issuance
47.00
+2.34%
45.93
0.00
—
Cash Dividends Paid
0.00
0.00
—
—
Proceeds From Stock Option Exercised
9.99
+20.08%
8.32
+1369.96%
0.57
+5.79%
0.54
Net Other Financing Charges
-88.94
-558.68%
19.39
-48.98%
38.01
—
Changes In Cash
-44.44
-406.72%
14.49
+121.01%
-68.97
-1.83%
-67.73
Beginning Cash Position
95.29
+17.93%
80.80
-46.05%
149.77
-31.14%
217.50
End Cash Position
50.85
-46.64%
95.29
+17.93%
80.80
-46.05%
149.77
Free Cash Flow
-105.93
-6.25%
-99.69
-31.90%
-75.58
-4.72%
-72.18
Interest Paid Supplemental Data
—
0.00
-100.00%
1.61
-39.54%
2.67
Common Stock Issuance
47.00
+2.34%
45.93
0.00
—
Interest Paid CFF
-0.04
0.00
—
—
Issuance Of Capital Stock
103.45
+16.17%
89.05
0.00
—
Net Preferred Stock Issuance
56.45
+30.90%
43.13
0.00
—
Preferred Stock Issuance
56.45
+30.90%
43.13
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category